FDA Approves Large-Volume Autoinjector for Adbry

The new 2 mL device lets patients receive the 300 mg dose of Adbry in one injection rather than two.

Updated on Nov. 6, 2026 in Asthma

Bold flat-color editorial illustration of a single unlabeled autoinjector housing in navy and cream with an amber accent, centered against a plain field. — The FDA approved a large-volume autoinjector for LEO Pharma's Adbry in October, letting patients take its 300 mg eczema dose in a single 2 mL injection. AI Illustration. Upload story photo >

In October 2026, the FDA approved a new 2 mL autoinjector for LEO Pharma's Adbry, a biologic treatment for moderate-to-severe eczema. The device delivers the 300 mg dose in a single injection, where previously patients needed two separate 1 mL injections.

Why it matters

Biologic therapies have traditionally been given at a clinic through intravenous infusion, so large-volume autoinjectors may allow more of these treatments to be self-administered at home. The change reduces the number of injections needed for the 300 mg dose.

The approval is for a 2 mL single-injection device that replaces two 1 mL injections for the 300 mg dose of Adbry. The source does not specify clinical outcome data or when the device will reach patients.

The players

LEO Pharma

LEO Pharma is a Danish biopharmaceutical company that develops treatments for skin diseases, including Adbry.

U.S. Food and Drug Administration

The FDA is the federal agency responsible for approving drugs and medical devices sold in the United States.

The details

The FDA approved a new large-volume autoinjector that delivers Adbry's 300 mg dose in one 2 mL injection. Adbry is used to treat moderate-to-severe eczema, and the change simplifies administration for patients who previously required two separate injections.

October 2026: FDA approves the new 2 mL autoinjector for Adbry.

Health Landscape

Biologic therapies have traditionally been administered at clinics by intravenous infusion, and large-volume autoinjectors are part of a shift toward home self-administration. This device extends that shift to a dose that previously required two separate injections.

Patients on the 300 mg Adbry dose may now receive it in one injection rather than two, reducing the number of injections per dose. The source does not say whether the device changes how or where patients obtain the drug.

The takeaway

Fewer injections per dose can make self-administered biologic treatment simpler for patients with chronic skin conditions. Patients should discuss device options with their prescribing clinician.